Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Ferraro

Showing results (41-50 of 124) with videos related to

Pageof 13
Sort By:
Journal of Neurology|December 24, 2017
Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?Jessica Frau, Luisa Maria Villar, Claudia Sardu, et al.
Journal of Neuroimmunology|November 15, 2019
Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosisMilena Nasi, Elena Bianchini, Sara De Biasi, et al.
Journal of Translational Medicine|April 18, 2020
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patientsMarco Chiarini, Ruggero Capra, Federico Serana, et al.
European Journal of Immunology|August 3, 2019
Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patientsSara De Biasi, Anna Maria Simone, Elena Bianchini, et al.
Current Medical Research and Opinion|May 17, 2014
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational studyEleonora Baldi, Angelica Guareschi, Francesca Vitetta, et al.
Journal of Neuroimmunology|May 23, 2020
Diagnostic features of initial demyelinating events associated with serum MOG-IgGRiccardo Orlandi, Sara Mariotto, Sergio Ferrari, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.
Nature Communications|March 30, 2024
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patientsSara De Biasi, Domenico Lo Tartaro, Anita Neroni, et al.
Molecular and Cellular Neurosciences|August 24, 2020
Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microgliaMilena Nasi, Anna De Gaetano, Elena Bianchini, et al.
Journal of Neurology|December 24, 2025
Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study)Clara Grazia Chisari, Salvatore Lo Fermo, Alessia Di Sapio, et al.
Pageof 13

Showing results (41-50 of 124) with videos related to

Sort By:
Pageof 13
Journal of Neurology|December 24, 2017
Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?Jessica Frau, Luisa Maria Villar, Claudia Sardu, et al.
Journal of Neuroimmunology|November 15, 2019
Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosisMilena Nasi, Elena Bianchini, Sara De Biasi, et al.
Journal of Translational Medicine|April 18, 2020
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patientsMarco Chiarini, Ruggero Capra, Federico Serana, et al.
European Journal of Immunology|August 3, 2019
Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patientsSara De Biasi, Anna Maria Simone, Elena Bianchini, et al.
Current Medical Research and Opinion|May 17, 2014
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational studyEleonora Baldi, Angelica Guareschi, Francesca Vitetta, et al.
Journal of Neuroimmunology|May 23, 2020
Diagnostic features of initial demyelinating events associated with serum MOG-IgGRiccardo Orlandi, Sara Mariotto, Sergio Ferrari, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.
Nature Communications|March 30, 2024
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patientsSara De Biasi, Domenico Lo Tartaro, Anita Neroni, et al.
Molecular and Cellular Neurosciences|August 24, 2020
Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microgliaMilena Nasi, Anna De Gaetano, Elena Bianchini, et al.
Journal of Neurology|December 24, 2025
Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study)Clara Grazia Chisari, Salvatore Lo Fermo, Alessia Di Sapio, et al.
Pageof 13